Skip to content
Triangle logo TriangleGet started
← KEYTRUDA: refractory Hodgkin Lymphoma

NCT00601718 · STUDY IN CONTEXT

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantl

Draft scope assessment: unclear. Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Maximum Tolerated Dose of Vorinostat

Source null

→

primary · POSTED

Common dose limiting toxicities.

Source null

→

primary · POSTED

Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy

Source null

→

primary · POSTED

Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-keytruda-7b74c3c0
nct id
NCT00601718
trial label
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantl
applicability
unclear
applicability note
Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
4
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0000
    source section id
    NCT00601718-om-0000
    source outcome index
    0
    endpoint
    Maximum Tolerated Dose of Vorinostat
    endpoint definition
    Maximum Tolerated Dose of Vorinostat
    time origin
    28 days post last dose of study drug
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0001
    source section id
    NCT00601718-om-0001
    source outcome index
    1
    endpoint
    Safety and Toxicity According to CTCAE v3.0
    endpoint definition
    Common dose limiting toxicities.
    time origin
    3-5 weeks post end of treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0002
    source section id
    NCT00601718-om-0002
    source outcome index
    2
    endpoint
    Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy
    endpoint definition
    Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy
    time origin
    3-5 weeks post end of treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0003
    source section id
    NCT00601718-om-0003
    source outcome index
    3
    endpoint
    Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment
    endpoint definition
    Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment
    time origin
    1-3 weeks post end of treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
    regimen
    Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
    analyzed count
    29
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00601718-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
    regimen
    Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
    analyzed count
    29
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00601718-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
    regimen
    Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
    analyzed count
    29
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00601718-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
    regimen
    Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
    analyzed count
    21
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00601718-om-0003#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-hodgkin-lymphoma-keytruda-7b74c3c0
    nct id
    NCT00601718
    harm key
    EG000
    source section id
    NCT00601718-ae
    event group key
    EG000
    event group label
    Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
    serious affected
    10
    serious at risk
    29
    other affected
    25
    other at risk
    29
    frequency threshold
    5
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice